Put These Two Promising Biotech Stocks on Your Watch List

by Louis Basenese, Small Cap and Special Situations Expert
Friday, November 6, 2009: Issue #1132

All the hoopla surrounding the biotech stock, Dendreon Corp. (Nasdaq: DNDN), this year is well deserved.

After all, the market potential for its prostate cancer treatment, Provenge, is significant. This year, 190,000 new cases of prostate cancer are expected, with 27,000 deaths from the disease. That makes it the most common non-skin cancer in the United States and the third most common cancer worldwide.

But Provenge takes a novel approach to treatment. The drug is the first active immunotherapy to improve survival by training a patient’s immune system to attack the cancer. And since it uses the body’s natural defenses, patients only report flu-like symptoms instead of the nasty side effects associated with chemotherapy.

This could have a far-reaching effect: If Dendreon’s methodology works to combat prostate cancer, it may also work in combating other cancers, too.

If so, then forget blockbuster… we’re talking mega-blockbuster here. Two Promising Biotech Stocks – Full Article

Latest From Our Experts

	Wealth Building: What If Jeremy Grantham is Right? by Alexander Green		Small Caps: Dendreon Corp. (Nasdaq: DNDN): Put These Two Promising Biotech Stocks on Your Watch List by Louis Basenese
	Energy & Infrastructure: Warren Buffett Goes “All in” on America… How to Play the Oracle’s Big Bet by David Fessler		Healthcare: The Stock Market’s Red Flags: Four Ways to Handle Potential Market Turmoil by Marc Lichtenfeld
	Options: The Married Put Option Strategy: The Smartest Way to Protect Against Downside by Karim Rahemtulla		Commodities: Oil Prices Are Headed to $90… How to Profit From the Move by Lee Lowell

Dendreon’s Reached Orbit… Now Who’s Next?

by Robert Williams, Publisher

When the opening bell rang on Tuesday morning, as the broader market sagged, shares of Dendreon Corp. (Nasdaq: DNDN) sprinted out of the gates, rising by 5.7%.

Unless you live in a cave, you should know about this biotech stock.

Back in April, shares went “parabolic,” blasting 454% higher during the month.

(That’s not a typo. The stock increased almost five-fold over the course of a single month, rendering the S&P 500’s 10% gain over the same period completely insignificant.)

With an impressive move like that, you might think the run is over. But shares will likely head higher still… Full Article

Doctor Up Your Portfolio With This Medical Communications Company Beware This Tech-Tonic Shift In The Global Technology Sector Fuel Your Portfolio With BHP Billiton (NYSE: BHP): The Best-Run Commodities Company In The World » Blackboard Archives

We Respect Your Privacy

---

What is Investment U?

Since 1999, Investment U has provided impartial, no-nonsense investment advice on how to build long-lasting wealth.

---

Recent Articles

Platinum Services

The Oxford Club is an exclusive, global network of investors, who collectively participate in the pursuit of prosperity and wealth. The Club is renowned for its market-beating, tried-and-true investment principles.

The White Cap Report exclusively identifies companies, White Caps, which - by being among the earliest to gain traction - have secured dominant positions within untapped, billion-dollar markets.

With an elite trading team at the helm, the Xcelerated Profits Report shows any investor how to "invest like a pro," using high-level, yet easy-to-execute strategies that "xcelerate" profits while minimizing risk.

---